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After a vessel wall injury, platelets adhere to the subendothelium
following a sequence of events : arrest of single platelets on the
surface, progression to platelet spreading and final aggregation.
Primary arrest of circulating platelets on subendothelial compo-
nents occurs through platelet glycoprotein (GP) Ib and collagen
receptors ; then platelets spread and aggregate through a GPIIb-
IIIa-dependent mechanism. A series of strategies were applied to
analyse the tyrosine-phosphorylation mechanisms occurring at
the different stages of platelet adhesion on subendothelial compo-
nents under flow conditions, with special attention to primary
arrest. To evaluate spread platelets, samples were exposed to
acetylsalicylic acid, which blocks aggregate formation. To study
single platelets in contact, a monoclonal antibody specific for
GPIIb-IIIa was used to prevent platelet spreading and further
aggregation. This experimental situation was also investigated
using blood from two patients with Glanzmann’s thrombasthenia
(i.e. lacking GPIIb-IIIa). Results demonstrated that blockade of
INTRODUCTION
In response to blood vessel injuries, platelets interact with sites of
subendothelial exposure through primary adhesive mechanisms,
thereby promoting activation, spreading and finally aggregation
[1]. These processes take place under conditions of hydrodynamic
stress, and require sufficient adhesive strength, especially during
primary deposition of platelets [2,3]. During these events, dif-
ferent signalling mechanisms occur to amplify platelet responses
[4], in order to bring about the formation of the haemostatic
plug.
Platelets contain a large number of non-receptor tyrosine
kinases that seem to be implicated in the regulation of agonist-
induced activation and subsequent platelet responses [5]. Most of
these mechanisms have been studied in platelets activated in
suspension, thus bypassing the adhesive function of platelets.
Under physiological conditions, platelets adhere to the exposed
subendothelium, which consists primarily of fibrillar collagen
and bound von Willebrand factor (vWF). The first contact of
platelets basically occurs through the interaction of platelet
glycoprotein (GP) Ib with vWF [6], which promotes the arrest of
platelets on the damaged surface and opposes shear forces [7].
This first arrest, in which the platelet cytoskeleton plays a major
role, facilitates the interaction of platelets with collagen receptors
[8]. After primary arrest occurs, functionally active GPIIb-IIIa
leads to platelet spreading and aggregate formation [9]. The
significance of the signalling processes occurring during the pro-
gression of platelet interaction with adhesive substrates remains
to be determined.
Abbreviations used: ASA, acetylsalicylic acid ; Col-I, purified type-I tendon collagen; ECL, enhanced chemiluminiscence; ECM, extracellular matrix ;
FAK, focal adhesion kinase ; GP, glycoprotein ; mAb, monoclonal antibody; vWF, von Willebrand factor.
1 To whom correspondence should be addressed (e-mail mdiaz!medicina.ub.es).
both spreading and aggregation results in significant changes in
the tyrosine-phosphorylation patterns. Arrest of single platelets
on collagen-rich surfaces resulted in phosphorylation of p125,
identified as focal adhesion kinase (FAK), the 80}85 kDa doublet
(cortactin), and p72, identified as Syk. Arrest of single platelets
on von Willebrand factor as adhesive substrate showed that
interaction through GPIb induces Syk phosphorylation, but not
that of cortactin and FAK. Our data indicate that the initial
arrest of platelets on subendothelial components involves Syk
phosphorylation, which seems to be GPIb-dependent, and this is
followed by activation and phosphorylation of cortactin and
FAK. These processes seem to occur before GPIIb-IIIa becomes
activated.
Key words: adhesion, glycoproteins, perfusion chamber, von
Willebrand factor.
Upon stimulation of platelets, multiple proteins become phos-
phorylated at tyrosine residues [10]. This process is mediated by
at least three families of tyrosine kinases, Src, Syk and focal
adhesion kinase (FAK) [11]. It is currently accepted that tyrosine
phosphorylation of proteins in platelets activated in suspension
occurs in successive waves, depending on the activation state of
GPIIb-IIIa [12], and consists of early activation, cross-linking
of GPIIb-IIIa and final aggregation. Although the signalling pro-
cesses involved in shape change and aggregation are beginning to
be elucidated, the mechanisms that take place during primary
arrest and further activation of platelets adhering on to substrates
under flow conditions remain unclear.
The present study was undertaken to elucidate the signalling
processes, occurring through tyrosine phosphorylation, during
interaction of platelets with subendothelial components, under
flow conditions. For this purpose, we investigated changes in
tyrosine phosphorylation of proteins during primary arrest of
platelets on extracellular matrix (ECM), generated by endothelial
cells in culture, and on purified type-I tendon collagen (Col-I) by
inhibiting both platelet spreading and aggregate formation. In
some experiments, vWF was used as the adhesive substrate. To
evaluate spread platelets, samples were exposed to acetylsalicylic
acid (ASA), an agent that blocks aggregate formation. To study
single platelets in primary arrest stages, samples were preincu-
bated with an antibody to GPIIb-IIIa, since this GP is involved
in platelet spreading and aggregation. Further studies were
performed using blood samples from two patients with Glanz-
mann’s thrombasthenia, whose platelets totally lacked GPIIb-
IIIa.
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MATERIALS AND METHODS
Experimental design
The present study was designed to evaluate the signal transduc-
tion processes occurring through tyrosine phosphorylation after
platelet activation by adhesion, under flow conditions, and to
determine which phosphotyrosine proteins are implicated in
primary arrest of platelets on adhesive surfaces. For this purpose,
adhesion experiments were performed using different adhesive
substrates : coverslips were coated with ECM generated by
endothelial cells in culture, Col-I or vWF. Perfusions were
carried out with blood samples containing platelets before and
after incubation with ASA or an anti-GPIIb-IIIa monoclonal
antibody (mAb), using a parallel-plate perfusion chamber. After
5 min of perfusion, adhered platelets were solubilized, and
proteins were resolved by SDS}PAGE (8% gels), followed by
Western blotting to detect phosphotyrosine proteins. Tyrosine
phosphorylation occurring in GPIIb-IIIa-deficient platelets ad-
hered on collagen, under flow conditions, was also evaluated.
Routine en face evaluation was performed to quantify the surface
covered by platelets.
The present study required blood samples from healthy
volunteers and from two patients with type I Glanzmann
thrombasthenia. Research was carried out in accordance with the
Declaration of Helsinki of the World Medical Association,
the Ethical Committee of the Institution approved it, and the
subjects included gave informed consent to the work.
Antibodies and chemical reagents
Col-I was obtained from Chrono-log Corporation (Havertown,
PA, U.S.A.), and Haemate-P, used as a source of vWF, was from
Aventis Behring (Barcelona, Spain). Recombinant anti-phospho-
tyrosine (RC20) and anti-FAK mAbs were purchased from
Transduction Laboratories (Lexington, KY, U.S.A.). Anti-cor-
tactin (p80}85) clone 4F11 and anti-Syk clone 4D10.1 mAbs
were from Upstate Biotechnology (Lake Placid, NY, U.S.A.).
Fab fragments of the chimaeric anti-GPIIb-IIIa mAb (7E3;
ReoPro2) were from Lilly S.A. (Geneva, Switzerland). PBS,
Medium 199, glutamine, penicillin and streptomycin were ob-
tained from Gibco BRL, Life Technologies S.A. (Barcelona,
Spain). ASA, adenosine, apyrase, benzamidine, EGTA, leupep-
tin, PMSF, pepstatin and orthovanadate were purchased from
Sigma (St. Louis, MO, U.S.A.). Protein A–Sepharose was
from Pierce (Rockford, IL, U.S.A.), and electrophoresis reagents
and nitrocellulose membranes were from Bio-Rad Laboratories
S.A. (Madrid, Spain). Enhanced chemiluminiscence (ECL) re-
agents and Hyperfilm-ECL were from Amersham Pharmacia
Biotech Europe GmbH (Barcelona, Spain)
Preparation of the perfusates
Whole blood samples anti-coagulated with citrate}phosphate}
dextrose (100 mM sodium citrate, 16 mM citric acid, 18 mM
sodium hydrogen phosphate and 130 mM dextrose) (at a final
citrate concentration of 19 mM) were obtained from healthy
volunteers who had not taken any drugs affecting platelet
function in the previous 10 days. Anti-coagulated blood samples
were separated into plasma, washed red cells and washed platelets
[13]. The washed platelets were then divided into three portions ;
one was kept untreated (control), a second one was incubated
with 100 µM ASA (final concentration in blood), and a third one
was incubated with the anti-GPIIb-IIIa mAb (10 µg}ml, final
concentration in blood). Incubations were performed for 30 min
at 37 °C. Plasma and washed red cells were then added back to
each of these three platelet preparations to yield three samples of
reconstituted whole blood (40% haematocrit and 1.2¬10&
platelets}ml, final concentrations). In some experiments, apyrase
was added to a final concentration of 1 unit}ml to remove ADP
that might be released from platelets.
Aliquots (20 ml) of whole blood from healthy volunteers and
from two patients with type I Glanzmann’s thrombasthenia were
used for the perfusion studies.
Isolation of endothelial cell ECMs
Endothelial cells were isolated from human umbilical veins with
collagenase (0.2% in PBS; for 15 min at 37 °C), as previously
described [14], with minor modifications [15]. Cells were main-
tained and subcultured at 37 °C in a 5% CO
#
humidified
incubator in Medium 199 supplemented with 2 mM glutamine,
100 units}ml penicillin, 100 µg}ml streptomycin and 20% (v}v)
pooled human serum. The culture medium was changed every
48 h. The cells were identified as endothelial cells both morpho-
logically and by the presence of vWF, as detected by immuno-
fluorescence. After the second passage, the cells were subcultured
to confluence on 1% (w}v) gelatin-coated glass coverslips. After
confluence, cells were detached to obtain the ECM by treatment
with 3% (w}v) EGTA for 60 min at 37 °C.
Coating of coverslips with purified adhesive proteins
Col-I was sprayed with an air brush on to 18¬18 mm# plastic
coverslips in order to achieve a density of 100 µg}coverslip. vWF
was sprayed in order to achieve a density of 1 unit}coverslip.
Coverslips were kept at 4 °C overnight [13].
Perfusion studies
Adhesion studies were carried out using a parallel-plate perfusion
chamber [16,17], using coverslips coated with the ECM produced
by endothelial cells in culture, with Col-I or with vWF. For each
perfusion, two coverslips were individually inserted into the
separate receptacles of a parallel-plate perfusion chamber. Blood
samples were recirculated through the perfusion chamber at a
shear rate of 800 s−" for 5 min. After perfusion, coverslips were
rinsed with 0.15 M PBS. One of the two perfused coverslips was
processed for light microscopy analysis. The remaining coverslip
was incubated at 4 °C with Laemmli’s buffer [125 mM Tris}HCl,
2% (w}v) SDS, 5% (v}v) glycerol and 0.003% Bromophenol
Blue] containing 2 mM orthovanadate and 0.625 mg}ml N-
ethylmaleimide for 15 min. Platelets adhered on the perfused
surface of the coverslip were then removed by scraping and the
total lysate was collected in an Eppendorf tube and heated at
90 °C for 5 min. Samples were kept at ®20 °C until electro-
phoretic analysis.
Morphometric analysis
For morphometric analysis, one of the two perfused coverslips
was fixed with 0.5% glutaraldehyde in 0.15 M PBS at 4 °C for
24 h, and then stained with 0.02% Toluidine Blue and morpho-
metrically evaluated. The degree of platelet deposition on the
perfused surface was evaluated en face by means of an automated
method [18]. Images from the perfused surface were captured by
a video camera (Leica) connected to a light microscope (Polyvar;
Reichert–Jung, Vienna, Austria). The video camera provided
images to the automated image analysis system (SigmaScan;
Jandel Scientific software) which was connected to a PC computer
with a graphic card adapter. A software package provided
specialized programs to determine the surface covered as a
percentage of the total area screened.
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Figure 1 Platelet interaction with the ECM generated by endothelial cells in culture : effects of ASA and a mAb specific for GPIIb-IIIa (7E3)
Panel I : micrographs show grouped (aggregated) or single platelets, as they appear after en face visualization, adhered on ECM-coated coverslips after perfusion with blood samples at 800 s−1,
for 5 min. Adhered platelets were stained with Toluidine Blue. (A) Blood samples containing non-treated platelets, which were able to form aggregates on the ECM. (B) Blood samples containing
platelets treated with ASA, which resulted in a decrease in aggregate formation with an increase in the surface covered by platelets. (C) Only single platelets in contact with the ECM were observed
when blood samples contained platelets previously treated with Fab fragments of 7E3. Panel II : profiles of tyrosine-phosphorylated proteins from non-activated platelets in suspension (lane 1),
and platelets interacting with ECM in the absence of anti-platelet agents (lane 2), in the presence of ASA (lane 3), and in the presence of Fab fragments of 7E3 (lane 4). Micrographs and profiles
shown are representative of six different experiments. Scale bar¯ 15 µm.
Evaluation of phosphotyrosine proteins
Lysates of platelets activated by adhesion on ECM, Col-I or
vWF were resolved by SDS}PAGE (8% gels) [19]. Proteins
present in the gels were transferred on to nitrocellulose mem-
branes [20]. After blocking for non-specific binding, Western-
blots were probed with a horseradish peroxidase-conjugated
anti-phosphotyrosine recombinant antibody (RC20; 1:2500 di-
lution). Excess antibody was removed by extensive washing, and
blots were developed by ECL [21].
Immunoprecipitation studies
Reconstituted blood samples containing platelets previously
incubated with an antibody specific for GPIIb-IIIa were used as
perfusates for immunoprecipitation studies. Samples were then
perfused on coverslips coated with Col-I or vWF, as described
before.
Adhered platelets were solubilized in ice-cold modified radio-
immune precipitation buffer [50 mM Tris}HCl (pH 7.4), 1%
(v}v) Nonidet P40, 0.25% sodium deoxycholate and 150 mM
NaCl] containing 1 mM EGTA, 1 mM PMSF, 1 mM NaF,
1 µg}ml leupeptin, 1 µg}ml pepstatin and 1 mM sodium ortho-
vanadate, as protease and phosphatase inhibitors. Following
removal of insoluble material by centrifugation at 14000 g for
1 min, at 4 °C, aliquots of the lysates containing equal amounts
of protein were incubated overnight with either anti-FAK (p125)
or anti-cortactin (p80}85) antibodies. Immune complexes were
captured with affinity-purified rabbit anti-mouse IgG coupled to
Protein A–agarose. Immunoprecipitates were recovered in Laem-
mli’s buffer under reducing conditions, subjected to SDS}PAGE
and transferred on to nitrocellulose membranes. To detect
tyrosine phosphorylation of the immunoprecipitated proteins,
membranes were probed with horseradish peroxidase-conjugated
anti-phosphotyrosine antibodies (RC20; 1:2500 dilution).
The presence of the blotted proteins was checked by probing the
membranes with specific antibodies.
Statistics
Statistical analysis was performed using Student’s t test ; P! 0.05
was considered statistically significant.
RESULTS
Platelet activation by adhesion on endothelial cell ECM under
flow conditions
Adhesion studies were performed using a parallel-plate per-
fusion chamber on coverslips with ECM at 800 s−" for 5 min.
After perfusions, coverslips were processed to analyse the sur-
face covered by platelets, expressed as the percentage of surface
coverage, and to assess changes in tyrosine phosphorylation of
proteins in the adhered platelets.
The surface coverage on ECM after being perfused with
control blood samples was 25.05³1.8% (mean³S.E.M., n¯
12) (Figure 1, panel IA). Treatment of perfusates with ASA
resulted in a significant increase in the surface coverage to
51.8³2.9% (mean³S.E.M., n¯ 6; P! 0.001) with a decrease
in aggregate formation, as shown by the lower intensity of
staining (Figure 1, panel IB). Results were significantly different
when the perfusates were preincubated with an anti-GPIIb-IIIa
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Figure 2 Platelet interaction with Col-I under flow conditions : effects of ASA and a mAb specific for GPIIb-IIIa (7E3)
Panel I : micrographs show grouped or single platelets, visualized en face after staining with Toluidine Blue, adhered on Col-I fibres perfused with blood samples at 800 s−1, for 5 min. (A) The
coverslips coated with Col-I fibres were perfused with blood samples containing non-treated platelets that formed aggregates on the surface. (B) Blood samples containing platelets treated
with ASA, which resulted in a decrease in aggregate formation with an increase in the surface covered by platelets. (C) Only single platelets in contact with the Col-I fibres were observed when
blood samples contained platelets previously treated with Fab fragments of 7E3. Panel II : profiles of tyrosine-phosphorylated proteins from non-activated platelets in suspension (lane 1), and platelets
interacting with Col-I in the absence of antiplatelet agents (lane 2), in the presence of ASA (lane 3), and in the presence of an anti-GPIIb-IIIa mAb (lane 4). Lane 5 corresponds to platelets from
a patient with Glanzmann’s thrombasthenia interacting with Col-I. Panels III and IV : blots re-probed with anti-p80/85 or anti-pp125 antibodies respectively, to verify equal amounts of cortactin
and FAK in all samples. Micrographs and profiles shown are representative of six different experiments. Scale bar¯ 15 µm.
mAb. The presence of the antibody completely inhibited ag-
gregate formation, resulting in single platelets in contact (Figure
1, panel IC), and reaching a surface coverage of 12.7³2.5%
(mean³S.E.M., n¯ 6; P¯ 0.001).
Interaction of platelets with ECM resulted in the phosphory-
lation of multiple proteins at tyrosine residues (Figure 1, panel
II). Phosphorylation levels in ASA-treated platelets spread on
ECM were qualitatively and quantitatively equal to those ob-
served in non-treated samples (Figure 1, panel II, compare lanes
3 and 2). In contrast, tyrosine phosphorylation of proteins was
partially inhibited by the presence of the anti-GPIIb-IIIa mAb.
Only proteins p125, p80, p72 and p60 were consistently phos-
phorylated (Figure 1, panel II, compare lanes 4 and 2).
Platelet activation by adhesion on Col-I under flow conditions
A similar experimental approach was applied using Col-I as
the adhesive substrate. The surface coverage on Col-I after
perfusion with control samples was 34.2³1.7% (mean³S.E.M.,
n¯ 12), with formation of large aggregates (Figure 2, panel IA).
Preincubation of perfusates with ASA (Figure 2, panel IB)
resulted in a decrease in aggregate formation on Col-I, although
the percentage of surface coverage was slightly higher than in
controls due to an increase in platelet spreading (37.1³1.6%
compared with 34.2³1.7%, n¯ 6). Pre-treatment of blood
perfusates with an anti-GPIIb-IIIa mAb (Figure 2, panel IC), for
30 min before perfusion, resulted in a significant reduction in
the surface of Col-I covered by platelets, from 34.2³1.7%
(in control experiments) to 19.7³0.8% with single platelets in
contact (mean³S.E.M., n¯ 6, P! 0.001).
Under the experimental conditions applied, patterns of tyro-
sine-phosphorylated proteins observed in platelets interacting
with Col-I were the same as those in platelets adhered on ECM.
The presence of ASA did not modify these protein profiles
(Figure 2, panel II, lane 3 compared with lane 2). However,
perfusion of Col-I-coated coverslips with perfusates containing
anti-GPIIb-IIIa mAb resulted in qualitative and quantitative
differences in the tyrosine-phosphorylation patterns observed in
the arrested platelets. Phosphorylation levels were in general
weaker than in controls. Only proteins p125, p80, p72 and pp60
were clearly phosphorylated.
The effect of apyrase was assayed to evaluate the role of ADP
released from platelets in this experimental model. No differences
in the adhesion patterns or in the protein profiles were detected
by the addition of apyrase to the platelet suspension buffers.
Tyrosine phosphorylation in GPIIb-IIIa-deficient platelets
interacting with Col-I under flow conditions
Interaction of platelets from two patients with Glanzmann’s
thrombasthenia was also assessed on Col-I, under flow condi-
tions. After 5 min of perfusion, only single platelets in contact
with the collagen surface could be observed, leading to a surface
coverage of 21³3.7% (mean obtained from the analysis of 20
microscopic fields per coverslip, considering that the experiments
were repeated three times).
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Figure 3 Identification of tyrosine-phosphorylated proteins in platelets
interacting with Col-I and with vWF: effect of Fab fragments of a mAb
specific for GPIIb-IIIa (7E3)
Immunoprecipitation experiments were performed using samples corresponding to non-
activated platelets in suspension (Non Adh) and platelets adhered on Col-I or vWF, as indicated.
Adhesion studies were performed under flow conditions using blood samples containing non-
treated platelets (®7E3) or platelets previously incubated with Fab fragments of a mAb specific
for GPII-IIIa (­7E3). (A) Samples were immunoprecipitated with an anti-p80/85 (cortactin)
antibody. The immunoprecipitates were resolved by SDS/PAGE (8% gels) and proteins
transferred on to nitrocellulose membranes to detect tyrosine phosphorylation of p80/85
cortactin by a specific antibody (blot α-PY). Presence of cortactin or Syk were checked in the
membranes with the appropriate antibodies (blot α-cortactin and blot α-Syk). (B) Samples were
immunoprecipitated with an anti-pp125Fak antibody. The immunoprecipitates were treated as
indicated previously to detect phosphorylation (blot α-PY) and the presence (blot α-FAK) of
pp125FAK. Profiles shown are representative of six different experiments.
The congenital absence of GPIIb-IIIa resulted in tyrosine-
phosphorylation patterns comparable with those observed in
control adhered platelets previously incubated with the anti-
GPIIb-IIIa mAb. Proteins p80, p72 and pp60 appeared clearly
phosphorylated at tyrosine residues. An increase in the time of
exposure of the radiograph film to the nitrocellulose membrane
did not modify the protein profiles (Figure 2, panel II, lane 5).
Immunoprecipitation of cortactin and FAK
When nitrocellulose membranes, containing phosphotyrosine
protein profiles from adhered platelets either in the absence or in
the presence ofASA, the anti-GPIIb-IIIa mAbor thrombasthenic
platelets, were probed with antibodies against cortactin (p80}85)
and FAK, both proteins were found to be present (Figure 2,
panels III and IV).
To confirm that tyrosine-phosphorylated proteins p80 and
p125 corresponded to cortactin and FAK, we performed im-
munoprecipitation studies with specific antibodies. Experiments
were carried out using blood samples containing non-treated
platelets or platelets previously incubated with an anti-GPIIb-
IIIa mAb. Samples were perfused on to Col-I as the adhesive
substrate. Both proteins, cortactin and FAK, were found to be
present in platelets and became phosphorylated after adhesion to
the collagen surface (Figure 3). Interestingly, when probing
phosphorylation of cortactin, a protein of 72 kDa was also
detected, which was identified as Syk by a specific antibody
(Figure 3). The presence of the anti-GPIIb-IIIa mAb did not
inhibit the phosphorylation of any of the previously mentioned
proteins under these experimental conditions (Figure 3).
Immunoprecipitation of cortactin and FAK in platelets interacting
with vWF
Adhesion studies were also performed using vWF as the adhesive
substrate, applying the same experimental design as for Col-I.
Perfusions were carried out with blood containing non-treated
platelets or platelets previously incubated with an anti-GPIIb-
IIIa mAb. Morphometric evaluation of the perfused coverslips
was performed to verify the effect of the anti-GPIIb-IIIa mAb.
The surface coverage reached on vWF was 34.9³1.9% (mean³
S.E.M., n¯ 4) in the absence of the antibody, and 13.9³0.5%
(n¯ 4, P! 0.001) with single platelets in contact in the presence
of the anti-GPIIb-IIIa mAb.
Immunoprecipitation of both cortactin and FAK were also
performed (see Figure 3). Both proteins were present in lysates
corresponding to platelets interacting with vWF in the absence
and in the presence of anti-GPIIb-IIIa mAb. Immunoprecipita-
tion of cortactin resulted in the co-immunoprecipitation of a
protein of 72 kDa, identified as p72syk (Figure 3). While cortactin
and FAK appeared tyrosine-phosphorylated in the absence of
the mAb, blockade of GPIIb-IIIa resulted in complete inhibition
of the phosphorylation of both proteins at tyrosine residues.
However, phosphorylated p72syk was detected even in the pres-
ence of the anti-GPIIb-IIIa mAb (Figure 3).
DISCUSSION
Effective primary haemostasis depends on rapid recognition of
the damaged surface by circulating platelets, thereby promoting
initial platelet contact and further platelet activation [1,22].
These processes proceed through well synchronized signalling
mechanisms to maintain platelet function [23]. We have found
that the pattern of tyrosine phosphorylation in adherent platelets
is determined by the nature of the adhesive substrate to which
they are attached. Data from the present study indicate that
arrest of single platelets on collagen triggers a series of signalling
events differing from those observed by further activation to
spreading and aggregation. Furthermore, our results indicate
that phosphorylation of p72syk, p80}85 (cortactin) and pp125FAK
is specifically involved in the initial arrest of platelets on collagen
and seems to occur before GPIIb-IIIa becomes activated.
During the interaction of platelets with subendothelial struc-
tures, the intensity of platelet response depends on the severity of
the vascular damage [24]. Primary haemostasis is related to the
limited interaction of platelets with the ECM exposed after
superficial endothelial denudation. However, platelet interactions
with a collagen-rich surface are related to deep vascular damage
and acute thrombotic events, which could trigger a more intense
cascade of signalling mechanisms [23]. Tyrosine phosphorylation
of proteins is one of the signalling mechanisms that regulates cell
responses [25], and which has been extensively studied in platelets
activated in suspension [5,26]. Our present study has considered
that platelets fulfil their main function by interacting with the
subendothelium under flow conditions. From this perspective,
we have evaluated the signalling processes occurring during
platelet interaction with different adhesive substrata under flow
conditions, taking into consideration that this interaction occurs
following a sequence of events that involves primary arrest,
spreading and aggregation.
When evaluating platelet interaction with the ECM, we were
able to stop platelets at arrest stages by using inhibitory strategies
to block GPIIb-IIIa, resulting in dramatic changes in tyrosine
phosphorylation of several proteins. Interestingly, when platelets
were allowed to spread but not to aggregate by ASA treatment
[27], the patterns of tyrosine phosphorylation found did not
differ from those observed after aggregation on ECM. The ECM
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is a complex matrix consisting of different adhesive proteins to
which platelets adhere through multiple receptors. To discern the
specific role of several primary platelet receptors in initiating
signalling through tyrosine phosphorylation we used purified
proteins, such as collagen and vWF, as adhesive substrates.
Collagen is the most important platelet-reactive protein present
in basement membranes, including the subendothelium. Al-
though many proteins have been proposed as collagen receptors,





(GPIa-IIa) [28] and the non-integrin receptors
GPIV [29] and GPVI [30]. The interaction of platelets with
collagen is complex and seems to occur following a biphasic
process [31]. Collagen is thought to be the major binding site for
vWF [32], which is recognized by platelet GPIb. Then, platelets
interact more rapidly and permanently with collagen probably
through GPIa-IIa. While GPIV seems to accelerate this process
[13], GPVI is necessary for full activation and aggregation of
platelets on the collagen surface under flow conditions [33].
In a previous study we demonstrated that activation of platelets
by adhesion on collagen induces tyrosine phosphorylation of
multiple proteins, which differ from those observed when ac-
tivation is induced in platelets in suspension [34]. In the present
study we observed that primary arrest of platelets, achieved in
the presence of a specific GPIIb-IIIa blocking antibody, occurs
with phosphorylation of only a few proteins : p72syk, p80}85
(cortactin) and pp125FAK. This experimental situation was re-
produced in those experiments in which the perfusates consisted
of blood samples from patients with a congenital deficiency of
GPIIb-IIIa. Glanzmann’s thrombasthenia not only provides a
unique model to assess the involvement of GPIIb-IIIa in platelet
function, but also to investigate the role of other receptors
implicated in those processes occurring independently of GPIIb-
IIIa. As expected, thrombasthenic platelets established contacts
on Col-I fibres, although they were unable to spread and
aggregate. Interestingly, proteins p72syk, p80}85 cortactin
and p125FAK also appeared in GPIIb-IIIa-deficient platelets in
contact with collagen. On the other hand, when control platelets
were allowed to spread in the presence ofASAno changes in terms
of tyrosine phosphorylation were apparent. These data together
with those observed on the ECM suggest that as spreading
occurs multiple proteins become tyrosine phosphorylated and
remain phosphorylated even when platelet-to-platelet interac-
tions have been inhibited by the presence of ASA.
The rational for the experimental design applied in the present
study was based on the fact that the main function of platelets
starts by interacting with subendothelial surfaces. Therefore our
main purpose was to investigate which signalling proteins are
involved in the arrest of platelets on subendothelial components
under flow conditions. Our results demonstrate that single
platelets arrested on collagen show phosphorylation of p72syk,
p80}85 (cortactin) and p125FAK. Cortactin has been identified as
a cytoskeleton-associated substrate for c-Src in transformed cells
[35]. In fact, phosphorylation of cortactin seems to play an
important role in modulating cell shape [36], and in promoting
platelet shape change in association with Syk [37]. Exposure
of collagen to circulating blood is followed by immobilization of
plasma vWF on the collagen surface by platelet GPIb, promoting
temporary arrest of platelets [7]. Considering that platelet arrest
on subendothelial surfaces is initially dependent on the in-
teraction of GPIb and vWF, which is stabilized by the connection
of GPIb to the cytoskeleton [39], it would have been reasonable
to suggest that pp80}85, together with Syk, could be one of the
earliest proteins involved in the signalling cascade during platelet
interaction. However, results from our present studies using
vWF as adhesive substrate, in the presence of anti-GPIIb-IIIa
mAb, indicate that primary platelet interaction through GPIb
induces phosphorylation of p72syk but not of cortactin. These
results are supported by a previous study by other authors
showing that vWF added to platelets in suspension in the
presence of botrocetin induces p72syk activation [40].
On the other hand, cortactin is supposed to be a substrate for
the tyrosine kinase Syk [37]. In our experimental setting, Syk
associated with cortactin appeared phosphorylated in those plate-
lets arrested on collagen even when GPIIb-IIIa was blocked.
Platelets, slowed by the interaction with vWF, bind to collagen
by collagen receptors, initially through the integrin GPIa-IIa
[41,31]. Our results would, therefore, support a role for collagen
receptors in further activation of protein p72syk, followed by
phosphorylation of cortactin, before GPIIb-IIIa becomes acti-
vated. These results would be in agreement with those from other
authors [42,43] that have indicated the involvement of a GPIa-
IIa-dependent pathway in signalling through Syk phosphory-
lation after collagen activation of platelets in suspension.
We also investigated the role of FAK under our experimental
conditions. Protein pp125FAK was initially shown to be localized
in focal adhesions in fibroblasts [44]. In platelets, phosphorylation
of pp125FAK has been associated with the aggregation process
[45], and with platelet spreading mediated by GPIIb-IIIa [46]. In
the present work, pp125FAK phosphorylation was inhibited by
the presence of anti-GPIIb-IIIa mAb when vWF was used as
adhesive substrate. In fact, platelet interaction with vWF occurs
through GPIb, followed by activation of GPIIb-IIIa, which
promotes platelet spreading and aggregation. However, when
using collagen as adhesive substrate, pp125FAK phosphorylation
occurred in GPIIb-IIIa-deficient platelets, again reinforcing a role
for other integrin receptors such as GPIa-IIa [47], a function-
ally significant collagen receptor in platelets.
Our study indicates that the initial arrest of platelets though
the interaction of GPIb with immobilized vWF involves phos-
phorylation of Syk. This first event is followed by activation and
phosphorylation of cortactin and FAK, processes that seem to be
dependent on collagen receptors. Both the binding of GPIb to
vWFand the interaction with collagen through collagen receptors
induces a conformational change in GPIIb-IIIa [38,48] that
enable the complex to bind to vWF. Therefore a second step
implies signalling during spreading and aggregate formation,
with both dependent on GPIIb-IIIa. We have been able to
identify specific signalling proteins during the primary arrest of
platelets. However, further studies are required to investigate
those proteins involved in signalling during platelet spreading
and aggregation on adhesive surfaces under flow conditions.
We express our gratitude to Dr G. A. Jamieson for his assistance in the preparation
of the manuscript. Support for these studies was provided by the Ministerio de
Ciencia y Tecnologı!a (SAF2000-0041 and HF1999-0059). This work was supported
in part by grants from the Fondo de Investigaciones de la Seguridad Social (FIS
98/321, 99/0110 and 99/0106) and the Generalitat de Catalunya (CIRIT SGR 99-
227 and 2001 TDOC 00002, personal grant to G.A.).
REFERENCES
1 Baumgartner, H. R. (1973) The role of blood flow in platelet adhesion, fibrin
deposition, and formation of mural thrombi. Microvasc. Res. 5, 167–179
2 Weiss, H. J., Turitto, V. T. and Baumgartner, H. R. (1978) Effect of shear rate on
platelet interaction with subendothelium in citrated and native blood. I. Shear rate-
dependent decrease of adhesion in von Willebrand’s disease and the Bernard-Soulier
syndrome. J. Lab. Clin. Med. 92, 750–764
3 Turitto, V. T. and Baumgartner, H. R. (1975) Platelet interaction with subendothelium
in a perfusion system : physical role of red blood cells. Microvasc. Res. 9, 335–344
4 Hawiger, J. (1989) Platelet secretory pathways : an overview. Methods Enzymol. 169,
191–195
5 Clark, E. A. and Brugge, J. S. (1993) Tyrosine phosphorylation in platelets – potential
roles in intracellular signal transduction. Trends Cardiovasc. Med. 3, 218–227
# 2002 Biochemical Society
71Tyrosine phosphorylation of proteins during primary arrest of platelets
6 Tschopp, T. B., Weiss, H. J. and Baumgartner, H. R. (1974) Decreased adhesion of
platelets to subendothelium in von Willebrand’s disease. J. Lab. Clin. Med. 83,
296–300
7 Savage, B., Saldivar, E. and Ruggeri, Z. M. (1996) Initiation of platelet adhesion by
arrest onto fibrinogen or translocation on von Willebrand factor. Cell (Cambridge,
Mass.) 84, 289–297
8 Santoro, S. A. (1988) Molecular basis of platelet adhesion to collagen. In Platelet
Membrane Receptors : Molecular Biology, Immunology, Biochemestry and Pathology
(Jamieson, G. A., ed.), pp. 291–314, Alan R. Liss, NY
9 Weiss, H. J., Turitto, V. T. and Baumgartner, H. R. (1991) Further evidence that
glycoprotein IIb-IIIa mediates platelet spreading on subendothelium. Thromb.
Haemostasis 65, 202–205
10 Golden, A. and Brugge, J. S. (1989) Thrombin treatment induces rapid changes in
tyrosine phosphorylation in platelets. Proc. Natl. Acad. Sci. U.S.A. 86, 901–905
11 Levy-Toledano, S. (1999) Platelet signal transduction pathways : could we organize
them into a ‘ hierarchy ’? Haemostasis 29, 4–15
12 Ferrell, Jr, J. E. and Martin, G. S. (1989) Tyrosine-specific protein phosphorylation is
regulated by glycoprotein IIb-IIIa in platelets. Proc. Natl. Acad. Sci. U.S.A. 86,
2234–2238
13 Diaz-Ricart, M., Tandon, N. N., Carretero, M., Ordinas, A., Bastida, E. and Jamieson,
G. A. (1993) Platelets lacking functional CD36 (glycoprotein IV) show reduced
adhesion to collagen in flowing whole blood. Blood 82, 491–496
14 Jaffe, E. A., Nachman, R. L. and Becker, C. G. (1973) Culture of human endothelial
cells derived from umbilical veins. Identification by morphologic and immunologic
criteria. J. Clin. Invest. 52, 2745–2756
15 Aznar-Salatti, J., Bastida, E., Haas, T. A., Escolar, G., Ordinas, A., de Groot, P. G. and
Buchanan, M. R. (1991) Platelet adhesion to exposed endothelial cell extracellular
matrixes is influenced by the method of preparation. Arterioscler. Thromb. 11,
436–442
16 Muggli, R., Baumgartner, H. R., Tschopp, T. B. and Keller, H. (1980) Automated
microdensitometry and protein assays as a measure for platelet adhesion and
aggregation on collagen-coated slides under controlled flow conditions. J. Lab. Clin.
Med. 95, 195–207
17 Sakariassen, K. S., Aarts, P. A., de Groot, P. G., Houdijk, W. P. and Sixma, J. J.
(1983) A perfusion chamber developed to investigate platelet interaction in flowing
blood with human vessel wall cells, their extracellular matrix, and purified
components. J. Lab. Clin. Med. 102, 522–535
18 Diaz-Ricart, M., Carretero, M., Castillo, R., Ordinas, A. and Escolar, G. (1994) Digital
image analysis of platelet-extracellular matrix interactions : studies in von Willebrand
disease patients and aspirin-treated donors. Haemostasis 24, 219–229
19 Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature (London) 227, 680–685
20 Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins
from polyacrylamide gels to nitrocellulose sheets : procedure and some applications.
Proc. Natl. Acad. Sci. U.S.A. 76, 4350–4354
21 Cichowski, K., McCormick, F. and Brugge, J. S. (1992) p21rasGAP association with
Fyn, Lyn, and Yes in thrombin-activated platelets. J. Biol. Chem. 267, 5025–5028
22 Weiss, H. J., Turitto, V. T. and Baumgartner, H. R. (1986) Platelet adhesion and
thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa,
Ib, and storage granules. Blood 67, 322–330
23 Kroll, M. H., Harris, T. S., Moake, J. L., Handin, R. I. and Schafer, A. I. (1991) von
Willebrand factor binding to platelet GpIb initiates signals for platelet activation.
J. Clin. Invest. 88, 1568–1573
24 Ip, J. H., Fuster, V., Israel, D., Badimon, L., Badimon, J. and Chesebro, J. H. (1991)
The role of platelets, thrombin and hyperplasia in restenosis after coronary
angioplasty. J. Am. Coll. Cardiol. 17, B77–B88
25 Hunter, T. (1995) Protein kinases and phosphatases : the yin and yang of protein
phosphorylation and signaling. Cell (Cambridge, Mass.) 80, 225–236
26 Levy-Toledano, S., Gallet, C., Nadal, F., Bryckaert, M., MacLouf, J. and Rosa, J. P.
(1997) Phosphorylation and dephosphorylation mechanisms in platelet function : a
tightly regulated balance. Thromb. Haemostasis 78, 226–233
27 Roux, S. P., Sakariassen, K. S., Turitto, V. T. and Baumgartner, H. R. (1991) Effect of
aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A
parallelism between in vivo and ex vivo thrombosis models. Arterioscler. Thromb. 11,
1182–1191
Received 7 December 2001/24 January 2002 ; accepted 27 February 2002
28 Nieuwenhuis, H. K., Akkerman, J. W., Houdijk, W. P. and Sixma, J. J. (1985) Human
blood platelets showing no response to collagen fail to express surface glycoprotein
Ia. Nature (London) 318, 470–472
29 Tandon, N. N., Kralisz, U. and Jamieson, G. A. (1989) Identification of glycoprotein IV
(CD36) as a primary receptor for platelet-collagen adhesion. J. Biol. Chem. 264,
7576–7583
30 Sugiyama, T., Okuma, M., Ushikubi, F., Sensaki, S., Kanaji, K. and Uchino, H. (1987)
A novel platelet aggregating factor found in a patient with defective collagen-induced
platelet aggregation and autoimmune thrombocytopenia. Blood 69, 1712–1720
31 Moroi, M., Jung, S. M., Nomura, S., Sekiguchi, S., Ordinas, A. and Dı!az-Ricart, M.
(1997) Analysis of the involvement of the von Willebrand factor-glycoprotein Ib
interaction in platelet adhesion to a collagen-coated surface under flow conditions.
Blood 90, 4413–4424
32 Sakariassen, K. S., Bolhuis, P. A. and Sixma, J. J. (1979) Human blood platelet
adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor
bound to the subendothelium. Nature (London) 279, 636–638
33 Moroi, M., Jung, S. M., Shinmyozu, K., Tomiyama, Y., Ordinas, A. and Dı!az-Ricart,
M. (1996) Analysis of platelet adhesion to a collagen-coated surface under flow
conditions : the involvement of glycoprotein VI in the platelet adhesion. Blood 88,
2081–2092
34 Arderiu, G., Estebanell, E., Pujol-Moix, N., Escolar, G., Ordinas, A. and Dı!az-Ricart, M.
(2000) Adherence of platelets under flow conditions results in specific
phosphorylation of proteins at tyrosine residues. Cell. Adhes. Commun. 7, 349–358
35 Wu, H., Reynolds, A. B., Kanner, S. B., Vines, R. R. and Parsons, J. T. (1991)
Identification and characterization of a novel cytoskeleton-associated pp60src
substrate. Mol. Cell. Biol. 11, 5113–5124
36 McNiven, M. A., Kim, L., Krueger, E. W., Orth, J. D., Cao, H. and Wong, T. W. (2000)
Regulated interactions between dynamin and the actin-binding protein cortactin
modulate cell shape. J. Cell Biol. 151, 187–198
37 Gallet, C., Rosa, J. P., Habib, A., Lebret, M., Levy-Toledano, S. and Maclouf, J.
(1999) Tyrosine phosphorylation of cortactin associated with Syk accompanies
thromboxane analogue-induced platelet shape change. J. Biol. Chem. 274,
23610–23616
38 Reference deleted
39 Fox, J. E. (1985) Linkage of a membrane skeleton to integral membrane
glycoproteins in human platelets. Identification of one of the glycoproteins as
glycoprotein Ib. J. Clin. Invest. 76, 1673–1683
40 Asazuma, N., Ozaki, Y., Satoh, K., Yatomi, Y., Handa, M., Fujimura, Y., Miura, S. and
Kume, S. (1997) Glycoprotein Ib-von Willebrand factor interactions activate tyrosine
kinases in human platelets. Blood 90, 4789–4798
41 Nieuwenhuis, H. K., Sakariassen, K. S., Houdijk, W. P., Nievelstein, P. F. E. M. and
Sixma, J. J. (1986) Deficiency of platelet membrane glycoprotein Ia associated with a
decreased platelet adhesion to subendothelium : a defect in platelet spreading. Blood
68, 692–695
42 Keely, P. J. and Parise, L. V. (1996) The α2β1 integrin is a necessary co-receptor for
collagen-induced activation of Syk and the subsequent phosphorylation of
phospholipase Cγ2 in platelets. J. Biol. Chem. 271, 26668–26676
43 Asazuma, N., Yatomi, Y., Ozaki, Y., Qi, R. M., Kuroda, K., Satoh, K. and Kume, S.
(1996) Protein-tyrosine phosphorylation and p72syk activation in human platelets
stimulated with collagen is dependent upon glycoprotein Ia/IIa and actin
polymerization. Thromb. Haemostasis 75, 648–654
44 Bockholt, S. M. and Burridge, K. (1995) An examination of focal adhesion formation
and tyrosine phosphorylation in fibroblasts isolated from src-, fyn-, and yes-mice.
Cell. Adhes. Commun. 3, 91–100
45 Lipfert, L., Haimovich, B., Schaller, M. D., Cobb, B. S., Parsons, J. T. and Brugge,
J. S. (1992) Integrin-dependent phosphorylation and activation of the protein tyrosine
kinase pp125FAK in platelets. J. Cell Biol. 119, 905–912
46 Ji, P. and Haimovich, B. (1999) Integrin αIIbβ3-mediated pp125FAK phosphorylation
and platelet spreading on fibrinogen are regulated by PI 3-kinase. Biochim. Biophys.
Acta 1448, 543–552
47 Polanowska-Grabowska, R., Geanacopoulos, M. and Gear, A. R. (1993) Platelet
adhesion to collagen via the α2β1 integrin under arterial flow conditions causes rapid
tyrosine phosphorylation of pp125FAK. Biochem. J. 296, 543–547
48 Nakamura, T., Kambayashi, J., Okuma, M. and Tandon, N. N. (1999) Activation of the
GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both
α2β1 integrin and GP VI. J. Biol. Chem. 274, 11897–11903
# 2002 Biochemical Society
